David Persing - Cepheid Insider

Cepheid -- USA Stock  

null 52.95  0.00  0.00%

Executive Vice President Chief Medical and Technology Officer, Director

Dr. David H. Persing M.D. Ph.D. is Executive Vice President Chief Medical and Technology Officer and Director of the Company
Age: 59  President Since 2005  Ph.D    
408 541-4191  www.cepheid.com
Persing first joined us as a director in May 2004, and became our Executive Vice President and Chief Medical and Technology Officer in August 2005. From 1999 to 2005, Dr. Persing was a research executive and Chief Scientific Officer at Corixa Corporationrationrationration, a Seattlebased biotechnology company, until its acquisition by GlaxoSmithKline. From 1990 to 1999 he was a member of the Clinical and Research Faculty of the Mayo Clinic in Rochester, Minnesota where he conducted research on hepatitis viruses, tickborne infections and molecular diagnostics. In 1992 he founded and directed the Molecular Microbiology Laboratory at Mayo Clinic. He has authored over 270 peerreviewed articles and has served as Editor in Chief for four textbooks on Molecular Diagnostics, the most recent of which was published by ASM press in 2011.

David Persing Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (0.06) % which means that it has lost $0.06 on every $100 spent on asset. This is way below average.
The company currently holds 281.63 M in liabilities with Debt to Equity (D/E) ratio of 0.76 which is about average as compared to similar companies. Cepheid has Current Ratio of 4.21 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Robert KatzIngersoll Rand Plc
N/A
Allisha ElliottSensata Technologies Holding N
2013
Henrik AncherJensenAgilent Technologies Inc
2013
Steven ReynoldsSensata Technologies Holding N
N/A
Paul CamutiIngersoll Rand Plc
2011
Joshua YoungSensata Technologies Holding N
2016
Jacob SayerSensata Technologies Holding N
2015
Patrick KaltenbachAgilent Technologies Inc
2014
Gary MichelIngersoll Rand Plc
2013
Dominique GrauAgilent Technologies Inc
2014
Alicia RodriguezAgilent Technologies Inc
N/A
Jacob ThaysenAgilent Technologies Inc
2014
Keith SultanaIngersoll Rand Plc
2015
Mark DoakAgilent Technologies Inc
2014
Hans LidforssSensata Technologies Holding N
N/A
Paul ChawlaSensata Technologies Holding N
N/A
Geert BraaksmaSensata Technologies Holding N
2014
Donald SimmonsIngersoll Rand Plc
2017
Todd WymanIngersoll Rand Plc
2015
Francesco IncalzaIngersoll Rand Plc
2016
Samraat RahaAgilent Technologies Inc
2017

Entity Summary

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and nonclinical markets. Cepheid (CPHD) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 1,700 people. Cepheid is listed under Measuring and Control Equipment category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Cepheid to your portfolio

Top Management

Cepheid Leadership Team
Thomas Gutshall, Director
Robert Easton, Director
Glenn Steele, Director
Thomas Brown, Director
Warren Kocmond, COO
Jacquie Ross, Executive
Kerry Flom, EVP, Ph.D
Daniel Madden, President
Michael Fitzgerald, EVP
Peter Farrell, EVP
David Persing, President, Ph.D
Scott Campbell, President, Ph.D
Marc Haugen, President
John Bishop, Chairman
Cristina Kepner, Director
Hollings Renton, Director
Joseph Smith, President

Stock Performance

Cepheid Performance Indicators